Axogen, Inc. Announces Third Quarter 2025 Financial Results
Axogen, Inc. (NASDAQ: AXGN), a pioneering company in the field of surgical solutions aimed at restoring peripheral nerve function, recently disclosed its financial results and notable developments for the third quarter of the year.
Financial Highlights of the Third Quarter
Summary of Financial Performance
- Third quarter revenue reached $60.1 million, indicating a remarkable 23.5% increase compared to the previous year and a 6.0% increase over the preceding quarter.
- The gross margin for this quarter stood at 76.6%, which is an improvement from 74.9% in the third quarter of last year and 74.2% in the previous quarter.
- Net income reported for the quarter was $0.7 million, equating to $0.01 per share, a substantial turnaround from a net loss of $1.9 million, or $0.04 per share, recorded in the third quarter of the previous year.
- Adjusted net income for the quarter was $6.1 million, or $0.12 per share, an increase from $3.1 million, or $0.07 per share, for the same period last year.
- Adjusted EBITDA was reported at $9.2 million for the quarter, showing growth from $6.5 million for the same period in 2024.
- As of September 30, 2025, the balance of cash and cash equivalents, restricted cash, and investments amounted to $39.8 million, reflecting an increase from $39.5 million at the end of December 2024.
CEO Statement
"Our performance in the third quarter highlights the robust growth of the peripheral nerve repair market. With revenue soaring 23.5% to $60.1 million and an adjusted EBITDA of $9.2 million, we are effectively scaling our commercial operations,” said Michael Dale, CEO and Director of Axogen, Inc.
Strategic Business Highlights
Overview of Business Developments
- Revenue growth in Q3 2025 was widespread, with all market segments, including Extremities, Oral Maxillofacial, and Breast, showing double-digit increases from the previous year.
- The American Association of Hand Surgery (AAHS) and the American Society for Reconstructive Microsurgery (ASRM) released new position statements in Q3 2025 recognizing nerve allograft as a standard practice for treating peripheral nerve defects. This recognition adds to the existing guidelines from the American Association of Oral and Maxillofacial Surgeons (AAOMS).
- The company has expanded coverage and reimbursement for nerve repair treatments, increasing the total number of covered lives to approximately 18.1 million, ensuring over 64% coverage among commercial payers.
- Additionally, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for the Avance Nerve Graft and has set a new goal date for approval.
Financial Outlook for 2025
Axogen has upgraded its revenue guidance for 2025 to reflect a growth target of at least 19%, estimating a revenue figure of $222.8 million. The company also anticipates maintaining a gross margin within the range of 73% to 75% for the year. However, one-time costs related to the expected BLA approval are expected to impact the gross margin negatively by about 1%, estimated at around $2 million. Despite these costs, Axogen expects to achieve net cash flow positive status for the year.
Upcoming Conference Call
The Company will conduct a conference call and webcast for investors today at 8:00 a.m. ET. Participants can join via phone by calling toll-free numbers provided by the company.
About Axogen
Axogen, Inc. is the foremost company dedicated to the science and commercial development of technologies aimed at peripheral nerve regeneration and repair. The company's committed employees strive to enhance patients' quality of life by providing innovative and clinically validated repair solutions for healthcare providers and surgeons.
Contact Information
For further inquiries, reach out to Axogen, Inc. at InvestorRelations@axogeninc.com.
Frequently Asked Questions
1. What were the key financial results for Axogen in Q3 2025?
In Q3 2025, Axogen reported revenues of $60.1 million, with a gross margin of 76.6% and a net income of $0.7 million.
2. How does the current revenue compare with past performance?
The current revenue represents a 23.5% year-on-year increase and a 6.0% quarter-on-quarter increase, indicating strong growth.
3. What major developments occurred for Axogen in Q3 2025?
Major developments included the FDA's acceptance of the BLA for Avance Nerve Graft and recognition of nerve allografts as standard practice by leading medical associations.
4. What is Axogen's guidance for 2025?
Axogen projects a revenue growth of at least 19% for 2025, aiming for total revenues of approximately $222.8 million.
5. How can I access more information about Axogen?
For comprehensive details, you can visit Axogen's official website at www.axogeninc.com.
